The past nine months have been rough ones to be an (NASDAQ: AGEN) shareholder. The stock has collapsed by about 75% from the peak it set last June.

Investment bank analysts on Wall Street who follow the Massachusetts-headquartered cancer drug developer think it's been underappreciated. For example, B. Riley recently reiterated a buy rating for Agenus with a $5 price target.

Agenus shares could deliver an enormous return if they get anywhere near Wall Street estimates. The stock has been trading below $1 per share since the company presented clinical trial results for its lead candidate last October.

Continue reading

Source Fool.com